Peritoneal Mesothelioma
Symptoms, diagnosis, staging and treatment options.
Overview
Peritoneal mesothelioma represents roughly 15% of all mesothelioma cases and accounts for approximately 500 new cases per year in the United States. In general, compared to patients with pleural mesothelioma, peritoneal mesothelioma patients have a better overall prognosis. Peritoneal mesothelioma involves the peritoneum, which is the lining of the abdominal cavity and occurs when asbestos fibers get into the body and travel to the abdomen where they become embedded in the peritoneum. It can take 20-50 years for asbestos in the abdomen to develop into peritoneal mesothelioma.
Symptoms
Initial symptoms of peritoneal mesothelioma are notoriously nonspecific, which often delays diagnosis. Because these symptoms mimic common conditions, it is often mistaken for irritable bowel syndrome, ovarian cancer, appendicitis or other abdominal problems, and often isn’t caught until disease has spread across peritoneal surfaces. Common symptoms of peritoneal mesothelioma include:
-
Abdominal distension/swelling – Often from fluid buildup, called ascites
-
Abdominal pain
-
Nausea
-
Bloating
-
Digestive problems
-
Weight loss
-
Occasionally a palpable abdominal mass
Symptoms will vary from patient to patient depending on a variety of factors.
Diagnosis
Diagnosing peritoneal mesothelioma usually involves several steps, since symptoms can overlap with other conditions. Imaging tests are often the first steps in diagnosing peritoneal mesothelioma and may include:
-
Abdomen/Pelvis CT Scan with Contrast – Provides detailed views of the peritoneum and extent of disease.
-
Abdomen FDG-PET Scan – Helps assess spread and distinguish cancerous from benign tissue.
-
Abdomen MRI – Sometimes used to evaluate disease burden in preparation for surgery.
Following imaging, the next steps in diagnosing peritoneal mesothelioma is obtaining fluid and tissue samples. If ascites is present, paracentesis (draining ascites with a needle to test for cancer cells) will often be performed. Paracentesis acts as both a symptom-relief treatment by draining excess fluid that restricts the abdomen, and serves as an initial diagnostic tool by providing samples to a laboratory for cytological examination (where a pathologist studies the cells under a microscope to look for malignant, cancerous cells). Due to the difficulty of diagnosing mesothelioma, fluid cytology on its own typically does not confirm peritoneal mesothelioma.
The definitive test for diagnosing peritoneal mesothelioma is a tissue biopsy, which range from minimally invasive needle approaches to surgical procedures depending on how much tissue is needed, where the disease is and the patient’s fitness for a procedure:
-
Laparoscopic Biopsy – Requires general anesthesia, but widely considered the preferred approach for diagnosis because it yields larger, better-quality tissue and lets the surgeon simultaneously asses disease extent and whether complete cytoreduction look feasible.
-
Image-Guided Percutaneous Needle Biopsy – Minimally invasive and often done under local anesthesia; good for accessible areas of peritoneal thickening, but less reliable when disease is patchy or small-volume.
-
Laparotomy – The most invasive procedure that is used when laparoscopy isn’t feasible/adequate or when more extensive surgical assessment is needed.
Staging
Unlike pleural mesothelioma, which uses the TNM staging system, the staging system for peritoneal mesothelioma is known as the Peritoneal Cancer Index (PCI). The PCI is a score-based system that measures how much cancer is present in the abdomen and how widely it has spread. It captures both where the disease is and how large the disease is in each area. The PCI is the main tool for planning surgery and estimating prognosis in peritoneal mesothelioma and is built from two simple ideas: dividing the abdomen into regions and scoring the size of any tumor in each region.
To calculate a patient’s PCI score, the first step is to divide the abdomen into 13 regions – 9 covering the main abdominal and pelvic areas and 4 covering the small bowel. The second step is to score the tumor size in each of the 13 regions by giving the largest tumor in each region a legion size (LS) score from 0 to 3:
-
LS-0 – No visible tumor
-
LS-1 – Tumor is small (up to approximately half a centimeter)
-
LS-2 – Tumor is medium (approximately half a centimeter to 5 centimeters)
-
LS-3 – Tumor is large (bigger than 5 centimeters) or many tumors have merged together
The final step is to add the 13 regional scores together for a total PCI score between 0 and 39. A lower score means less, more contained disease while a higher score means more extensive, widespread disease.
Treatments
Chemotherapy alone has been one of the backbones of mesothelioma treatment. For advanced/unresectable pleural mesothelioma, the combination of platinum plus antifolate was the standard of care until immunotherapy revolutionized the treatment of pleural mesothelioma in 2026. These therapies will be administered by medical oncologists:
Chemotherapy/Immunotherapy
Chemotherapy alone has been one of the backbones of mesothelioma treatment. For advanced/unresectable pleural mesothelioma, the combination of platinum plus antifolate was the standard of care until immunotherapy revolutionized the treatment of pleural mesothelioma in 2026. These therapies will be administered by thoracic medical oncologists:
-
Carboplatin (Paraplatin) or Cisplatin (Platinol) Plus Pemetrexed (Alimta) – This “platinum doublet” chemotherapy pairing has been the cornerstone of first-line treatment since 2004. Carboplatin is gentler than Cisplatin and is often used for older or less fit patients.
-
Ipilimumab (Opdivo) Plus Nivolumab (Yervoy) – A dual immune checkpoint blockade that helps the immune system recognize and attack the tumor, rather than attacking cancer cells directly like chemotherapy. This dual immunotherapy combination is strongly recommended for sarcomatoid and biphasic pleural mesothelioma, which have historically responded poorly to chemotherapy.
-
Carboplatin (Paraplatin) or Cisplatin (Platinol) Plus Pemetrexed (Alimta) Plus Pembrolizumab (Keytruda) – FDA-approved in 2024, this chemo-immunotherapy combination adds an immunotherapy boost to the familiar chemotherapy backbone and is appealing for epithelioid pleural mesothelioma or for patients where the treatment team wants chemotherapy’s direct tumor activity alongside immune activation.
-
Carboplatin (Paraplatin) or Cisplatin (Platinol) Plus Pemetrexed (Alimta) Plus Bevacizumab (Avastin) – Can sometimes extend survival in eligible patients when added to the traditional platinum doublet
-
Carboplatin (Paraplatin) or Cisplatin (Platinol) Plus Gemcitabine (Gemzar) – Sometimes offered when a patient can’t take Pemetrexed due to contraindications, intolerance or cost considerations.
-
Vinorelbine (Navelbine) – Typically offered second-line once a patient progresses on platinum doublet chemotherapy, but may be offered first-line to pleural mesothelioma patients who can’t tolerate or aren’t good candidates for platinum doublet chemotherapy or immunotherapy.
-
Pemetrexed (Alimta) – Sometimes offered second-line as maintenance monotherapy to continue disease control or first-line for selected elderly patients or those unfit for platinum doublet chemotherapy and immunotherapy.
-
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) – A cornerstone of treatment for eligible patients, HIPEC is almost always done in conjunction with cytoreductive surgery (CRS). It delivers heated chemotherapy (typically Cisplatin-based) directly into the abdominal cavity to kill microscopic disease left behind after surgery.
-
Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) – An early-stage, experimental procedure that is not combined with surgical removal of the main tumor. PITAC delivers chemotherapy as a pressurized aerosol mist into the pleural cavity via a special device, which spreads it evenly across the chest surfaces and helps it penetrate tumor tissue.
Surgery
Unlike pleural mesothelioma, peritoneal mesothelioma has one surgical procedure that is nearly always done in conjunction with a specific chemotherapy treatment. Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the cornerstone of treatment for eligible patients with peritoneal mesothelioma. CRS removes all visible mesothelioma from the abdomen – stripping affected peritoneum and resecting involved organs – with the goal of leaving no visible disease. It is typically reserved for fit patients with resectable (usually epithelioid) disease and is always performed by surgical oncologists.
An important aspect of CRS and its interplay with HIPEC is the Completeness of Cytoreduction score (CC score), which grades how much visible tumor remains after surgery. While the PCI measures disease before/during surgery, the CC score measures the result and is the single most important predictor of long-term survival. The CC score is a judgment by the surgeon of what’s left behind, based on inspecting the abdominal surfaces for any remaining tumor nodules. There are 4 different CC scores based on the size of the largest remaining tumor nodule:
-
CC-0 – No visible residual tumor. The ideal result where the surgeon sees no cancer remaining anywhere in the abdomen
-
CC-1 – Residual nodules 2.5 millimeters or smaller. Tiny amounts remain, but all are under the 2.5 millimeter threshold
-
CC-2 – Residual nodules between 2.5 millimeters and 2.5 centimeters
-
CC-3 – Residual nodules larger than 2.5 centimeters or extensive unresectable disease
CC-0 and CC-1 are considered “complete” cytoreduction because they fall within the 2-3 millimeter penetration limits of HIPEC. Anything at or below 2.5 millimeters can plausibly be killed by the HIPEC that follows CRS, while anything larger is beyond the reach of HIPEC and will likely survive. As a result, CC-2 and CC-3 are considered “incomplete” cytoreduction and typically indicate a worse prognosis.
Radiation
Radiation plays a much smaller role in peritoneal mesothelioma than in pleural. The fundamental problem is that the peritoneal cavity is full of radiation-sensitive organs and the dose needed to kill the diffuse-spread tumor would badly damage those organs. Despite these concerns, palliative radiation can occasionally be used to target discrete, symptomatic spots to relieve pain or pressure, but this is focused, not whole-abdomen treatment.
Clinical Trials
In large part due to clinical trials, the landscape for the treatment of peritoneal mesothelioma has changed more in the past six years then in the previous thirty. Because the standard treatment options for peritoneal mesothelioma are so limited – especially at the second-line, where there’s no approved standard therapy, trial enrollment is a compelling option for many patients. Due to the rarity of mesothelioma, much of the strongest future treatment evidence comes through trials, and access to the newest approaches often only comes through them. Peritoneal mesothelioma patients interested in exploring clinical trial options are encouraged to search for “peritoneal mesothelioma” on www.clinicaltrials.gov.
A note about this information
This information is general and educational, and isn’t a substitute for advice from a qualified medical professional. Anyone facing a mesothelioma diagnosis should discuss their specific situation with their care team.
We’re here to help.
Connect with Mesothelioma Options for help and support.
Help, hope and support.
You don’t have to navigate this alone. Contact Mesothelioma Options.